Literature DB >> 16186289

High plasma level of remnant-like particle cholesterol in the metabolic syndrome.

Akira Satoh1, Hisashi Adachi, Makoto Tsuruta, Yuji Hirai, Akiko Hiratsuka, Mika Enomoto, Kumiko Furuki, Asuka Hino, Tomohiro Takeuchi, Tsutomu Imaizumi.   

Abstract

OBJECTIVE: The metabolic syndrome is associated with a high incidence of cardiovascular disease even when the abnormalities present in the syndrome are mild. The underlying mechanism of the metabolic syndrome has not been elucidated. We investigated whether a strong atherogenic lipoprotein, remnant-like particle (RLP) lipoprotein cholesterol, is elevated in the metabolic syndrome. RESEARCH DESIGN AND METHODS: We performed a health examination among the residents of a rural community in Japan. Complete datasets, including fasting RLP cholesterol levels, were obtained in 1,261 subjects (509 men and 752 women) without diabetes and who were not taking lipid-lowering drugs. The subjects' medical history, use of alcohol, and smoking habits were ascertained by a questionnaire.
RESULTS: All of the components of the metabolic syndrome were significantly related to RLP cholesterol by univariate analysis. Total cholesterol and smoking habits were also positively associated with RLP cholesterol. The subjects with the metabolic syndrome showed only mild abnormalities of each component. When RLP cholesterol levels were stratified by the number of the components of the metabolic syndrome, there was a strong association between RLP cholesterol levels and the number of components (P < 0.001 and F = 72.7).
CONCLUSIONS: RLP cholesterol levels are elevated in the metabolic syndrome, and this elevation may underlie the high incidence of cardiovascular disease in the metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16186289     DOI: 10.2337/diacare.28.10.2514

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

2.  Natural killer (NK) cell deficit in coronary artery disease: no aberrations in phenotype but sustained reduction of NK cells is associated with low-grade inflammation.

Authors:  K Backteman; J Ernerudh; L Jonasson
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

3.  A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL₃+IDL]).

Authors:  Heidi T May; John R Nelson; Krishnaji R Kulkarni; Jeffrey L Anderson; Benjamin D Horne; Tami L Bair; Joseph B Muhlestein
Journal:  Lipids Health Dis       Date:  2013-04-26       Impact factor: 3.876

4.  High levels of remnant lipoprotein cholesterol is a risk factor for large artery atherosclerotic stroke.

Authors:  Jeong-Yeon Kim; Jong-Ho Park; Sang-Wuk Jeong; Dawid Schellingerhout; Jin-Eok Park; Dong Kun Lee; Won Jun Choi; Seok-Lae Chae; Dong-Eog Kim
Journal:  J Clin Neurol       Date:  2011-12-29       Impact factor: 3.077

5.  Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia.

Authors:  Hisashi Adachi; Hitoshi Nakano; Kiichiro Yamamoto; Masashi Nakata; Hisatoshi Bekki; Tomoki Honma; Hideki Yoshiyama; Masatoshi Nohara
Journal:  Lipids Health Dis       Date:  2015-01-10       Impact factor: 3.876

6.  Combined Effect of Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) and Remnant-Like Particle Cholesterol (RLP-C) on Low-Grade Inflammation.

Authors:  Toshihide Izumida; Yosikazu Nakamura; Yumika Hino; Shizukiyo Ishikawa
Journal:  J Atheroscler Thromb       Date:  2019-08-29       Impact factor: 4.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.